AbbVie (NYSE: ABBV) today announced that data for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) receptor antagonist, will be ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE